Evidence map›Paper›PMID 39821672›Full record

ArticleActa neuropathologica2025

Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.

Francesca Pagani, Francesca Orzan, Sara Lago, Francesca De Bacco, Marta Prelli, Manuela Cominelli, Elena Somenza, Magdalena Gryzik, Piera Balzarini, Davide Ceresa and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Francesca PaganiPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Francesca OrzanCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Turin, Italy.
Sara LagoLaboratory for Chromatin Biology and Epigenetics, CIBIO-Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.
Francesca De BaccoCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Turin, Italy.
Marta PrelliCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Turin, Italy.
Manuela CominelliPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Elena SomenzaPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Magdalena GryzikPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Piera BalzariniPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Davide CeresaIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Daniela MarubbiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Claudio IsellaCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Turin, Italy.
Giovanni CrisafulliIFOM ETS-The AIRC Institute of Molecular Oncology, 20139, Milan, Italy.
Maura PoliBiochemistry Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Paolo MalatestaIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Rossella GalliNeural Stem Cell Biology Unit, Division of Neuroscience, IRCCS San Raffaele Hospital, Milan, Italy.
Roberto RoncaExperimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Alessio ZippoLaboratory for Chromatin Biology and Epigenetics, CIBIO-Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.
Carla BoccaccioCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060, Turin, Italy.
Pietro Luigi PolianiPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. luigi.poliani@unibs.it.

Funding

Italian Association for Cancer Research N. 28836Ministero della Salute PNRR MNESYSMinistero della Salute RC 2022-2024Ministero della Salute RF-2016-02361014Ministero dell'Università e della Ricerca PRIN2020 cod. 20205TF444
6 · The paper itself

Abstract

The foremost feature of glioblastoma (GBM), the most frequent malignant brain tumours in adults, is a remarkable degree of intra- and inter-tumour heterogeneity reflecting the coexistence within the tumour bulk of different cell populations displaying distinctive genetic and transcriptomic profiles. GBM with primitive neuronal component (PNC), recently identified by DNA methylation-based classification as a peculiar GBM subtype (GBM-PNC), is a poorly recognized and aggressive GBM variant characterised by nodules containing cells with primitive neuronal differentiation along with conventional GBM areas. In addition, the presence of a PNC component has been also reported in IDH-mutant high-grade gliomas (HGGs), and to a lesser extent to other HGGs, suggesting that regardless from being IDH-mutant or IDH-wildtype, peculiar genetic and/or epigenetic events may contribute to the phenotypic skewing with the emergence of the PNC phenotype. However, a clear hypothesis on the mechanisms responsible for this phenotypic skewing is still lacking. We assumed that the biphasic nature of these entities represents a unique model to investigate the relationships between genetic alterations and their phenotypic manifestations. In this study we show that in HGGs with PNC features both components are highly enriched in genetic alterations directly causing cell cycle deregulation (RB inactivation or CDK4 amplification) and p53 pathway inactivation (TP53 mutations or MDM2/4 amplification). However, the PNC component displays further upregulation of transcriptional pathways associated with proliferative activity, including overexpression of MYC target genes. Notably, the PNC phenotype relies on the expression of EBF3, an early neurogenic transcription factor, which is directly controlled by MYC transcription factors in accessible chromatin sites. Overall our findings indicate that the concomitant presence of genetic alterations, impinging on both cell cycle and p53 pathway control, strongly predisposes GBM to develop a concomitant poorly differentiated primitive phenotype depending on MYC-driven EBF3 transcription in a subset of glioma stem-like progenitor cells.

Indexed as

Brain NeoplasmsGliomaProto-Oncogene Proteins c-mycRetinoblastoma Binding ProteinsTumor Suppressor Protein p53Ubiquitin-Protein LigasesAdultAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedSignal TransductionTrans-ActivatorsMYC protein, humanProto-Oncogene Proteins c-mycRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTrans-ActivatorsTumor Suppressor Protein p53Ubiquitin-Protein LigasesEarly B-cell factorGlioblastomaHigh-grade gliomaMYCPrimitive neuronal componentRB1Tumour heterogeneity

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.